| Identification | Back Directory | [Name]
HX 600 | [CAS]
172705-89-4 | [Synonyms]
HX 600
Benzoic acid,4-(7,8,9,10-tetrahydro-5,7,7,10,10-pentamethyl-5H-benzo[b]naphtho[2,3-e][1,4]diazepin-12-yl)- | [Molecular Formula]
C29H30N2O2 | [MDL Number]
MFCD29047012 | [MOL File]
172705-89-4.mol | [Molecular Weight]
438.56 |
| Chemical Properties | Back Directory | [Boiling point ]
589.6±50.0 °C(Predicted) | [density ]
1.17±0.1 g/cm3(Predicted) | [form ]
Solid | [pka]
3.03±0.10(Predicted) | [color ]
Yellow to orange |
| Hazard Information | Back Directory | [Description]
HX-600 is a synthetic agonist for the RXR-Nurr1 heterodimer complex. HX-600 prevents ischemia-induced neuronal damage. | [Uses]
HX600 is a synthetic agonist for RXR (Retinoid X Receptor) heterodimer complex. HX600 prevents ischemia-induced neuronal damage. HX600 has orally bioactivity[1]. | [in vivo]
HX600 (60 mg/kg; p.o.; every 24h) reduces ischemic damage and alleviates motor deficits in permanent ischemia model and Iba-1, phospho-p38 and TREM-2 immunoreactivities in the ischemic brain[1].
| Animal Model: | Ischemic Mice[1] | | Dosage: | 60 mg/kg | | Administration: | Oral Gavage (p.o.) | | Result: | Revealed that mice treated with HX600 had smaller lesion with the size of 21%, and significantly reduction in Iba-1, phospho-p38 and TREM-2 at protein level. |
| [IC 50]
RXR α: 1.9 μM (Ki); RXR β: 0.64 μM (Ki); RXR γ: 1 μM (Ki) | [References]
[1] Siddhesh S Kamat, et al. Immunomodulatory lysophosphatidylserines are regulated by ABHD16A and ABHD12 interplay. Nat Chem Biol 2015 Feb;11(2):164-71. DOI:10.1038/nchembio.1721
[2] Hiroki Umemiya, et al. Action Mechanism of Retinoid-Synergistic Dibenzodiazepines. Biochem Biophys Res Commun. 1997 Apr 7;233(1):121-5. DOI:10.1006/bbrc.1997.6414 |
|
|